Cellply Raises €7.15M for Cell Therapy Analytics Platform

Italian deep tech innovator Cellply has successfully secured €7.15 million in a funding round designed to fuel its international expansion and enhance its advanced cell therapy characterization platform. The investment, spearheaded by Enea Tech and Biomedical Foundation, with significant contributions from CDP Venture Capital and existing backers, signals strong confidence in Cellply's mission to standardize and scale the burgeoning field of cell-based therapeutics.

The newly acquired capital will be strategically deployed to accelerate the global rollout of Cellply's flagship product, the VivaCyte platform. This sophisticated system leverages proprietary microfluidics and AI-driven image analysis to provide single-cell resolution insights crucial for the development and quality control of cell therapies. Beyond market penetration, a portion of the funds will also advance the development of next-generation automated functional testing solutions. These are critical for improving the precision of potency assessments and streamlining batch release processes, persistent challenges hindering the widespread adoption of advanced therapy medicinal products (ATMPs).

Cellply's technology addresses a pivotal need within the rapidly evolving life sciences sector. As the industry pivots towards more complex and personalized treatments, the demand for robust, automated analytical tools that ensure consistency and efficacy is paramount. The global cell and gene therapy market, projected to reach tens of billions of dollars in the coming years, is heavily reliant on such innovations to move from niche applications to mainstream clinical practice. Cellply's approach aims to provide the foundational quality control infrastructure necessary for this transition.

The VivaCyte platform's unique architecture combines cutting-edge microfluidic chip design with automated image processing and dedicated software. This integrated solution offers researchers and manufacturers a comprehensive tool for characterizing therapeutic modalities, ensuring that the complex biological components meet stringent quality standards. The company emphasizes that standardized functional assays are not just beneficial but fundamental to achieving scalability, ensuring long-term sustainability, and ultimately broadening patient access to these potentially life-changing treatments worldwide.

In conjunction with this significant funding milestone, Cellply has bolstered its leadership team by welcoming Miro Venturi to its Board of Directors. Venturi brings a wealth of experience from the global diagnostics and life sciences industries, with a proven track record in scaling innovative healthcare solutions. His expertise is expected to be instrumental as Cellply navigates its international growth trajectory and deepens its commercial engagement across key global markets.

Alessia Zanelli, President and CEO of Cellply, expressed enthusiasm for the new investment, stating, “This investment provides the resources to accelerate our commercial expansion and advance innovative quality control solutions that can help unlock broader adoption of ATMPs worldwide.” Similarly, Miro Venturi commented on his appointment, noting Cellply's “highly differentiated technology platform addressing critical unmet needs in one of the most promising areas of healthcare innovation.”